Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting:
Authors:
- 1 February 2011
- journal article
- Published by Springer Nature in Drugs & Aging
- Vol. 28 (2) , 161-162
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The Clinically Important Difference on the Unified Parkinson's Disease Rating ScaleArchives of Neurology, 2010
- Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseCochrane Database of Systematic Reviews, 2009
- Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK SettingDrugs & Aging, 2009
- Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseMovement Disorders, 2009
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's diseaseEuropean Journal of Neurology, 2006
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseArchives of Neurology, 2004
- A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2004
- A Controlled Trial of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2002
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000